Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug-Reference-Cited by-同舟云学术

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

Published:2003-05-01 Issue:5 Volume:31 Page:645-651
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Clement Bernd,Lopian Katrin

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference33 articles.

1. Albert A, Goldacre R, and Phillips J (1948) The strength of heterocyclic bases. J Chem Soc 2240–2249..

2. Enzyme localization in the inner and outer membranes of rat liver mitochondria

3. Clement B (1993) Methoden zur Behandlung und Prophylaxe der Pneumocystis carinii pneumonie (PCP) und anderen Erkrankungen sowie Verbindungen und Formulierungen zum Gebrauch bei besagten Methoden. German patent, P 4321444.4, PCT/DE 94/00756(1994); USA (5, 786, 383;28/6/1998); Europe (0708640, 16/9/1998).

4. REDUCTION OFN-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES

5. Microsomal Catalyzed N-Hydroxylation of Guanabenz and Reduction of the N-Hydroxylated Metabolite: Characterization of the Two Reactions and Genotoxic Potential of Guanoxabenz1

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolism Studies In Vitro and In Vivo;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2024

2. The mitochondrial amidoxime reducing component—from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target;Journal of Biological Chemistry;2023-11

3. New Design of an Activity Assay Suitable for High-Throughput Screening of Substrates and Inhibitors of the Mitochondrial Amidoxime Reducing Component (mARC);Analytical Chemistry;2023-08-07

4. The History of mARC;Molecules;2023-06-12

5. Inhibitoren für Hydrolasen mit Acylenzym-Zwischenstufe;Wirkstoffdesign;2023